Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Sep;11(6):471-84.
doi: 10.2174/138920310791824011.

Merlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival

Affiliations
Review

Merlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival

Ivan Stamenkovic et al. Curr Protein Pept Sci. 2010 Sep.

Abstract

Genetic alterations of neurofibromatosis type 2 (NF2) gene lead to the development of schwannomas, meningiomas, and ependymomas. Mutations of NF2 gene were also found in thyroid cancer, mesothelioma, and melanoma, suggesting that it functions as a tumor suppressor in a wide spectrum of cells. The product of NF2 gene is merlin (moesin-ezrin-radixin-like protein), a member of the Band 4.1 superfamily proteins. Merlin shares significant sequence homology with the ERM (Ezrin-Radixin-Moesin) family proteins and serves as a linker between transmembrane proteins and the actin-cytoskeleton. Merlin is a multifunctional protein and involved in integrating and regulating the extracellular cues and intracellular signaling pathways that control cell fate, shape, proliferation, survival, and motility. Recent studies showed that merlin regulates the cell-cell and cell-matrix adhesions and functions of the cell surface adhesion/extracellular matrix receptors including CD44 and that merlin and CD44 antagonize each other's function and work upstream of the mammalian Hippo signaling pathway. Furthermore, merlin plays important roles in stabilizing the contact inhibition of proliferation and in regulating activities of several receptor tyrosine kinases. Accumulating data also suggested an emerging role of merlin as a negative regulator of growth and progression of several non-NF2 associated cancer types. Together, these recent advances have improved our basic understanding about merlin function, its regulation, and the major signaling pathways regulated by merlin and provided the foundation for future translation of these findings into the clinic for patients bearing the cancers in which merlin function and/or its downstream signaling pathways are impaired or altered.

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Exon organization and domain structure of merlin isoforms in relation to ezrin–radixin–moesin (ERM) proteins. A, The NF2 gene consists of 17 exons. Two most common merlin isoforms, isoform I and II, differ at their COOH-terminal ends with the segments, encoded by either exon 16 or 17, respectively. Merlin isoform I contains 595 amino acids whereas isoform II has 590 amino acids with estimated molecular weights of approximately 65-70 kDa. B, Domain organization and domain homology between merlin, band 4.1 protein, ezrin, radixin, and moesin are outlined.
Fig. (2)
Fig. (2)
A working model of merlin-mediated signaling events and their potential cross-talks (the components of Drosophila Hippo signaling pathway are underlined): merlin functions upstream of the mammalian Hippo (merlin-MST1/2-LATS1/2-YAP) and JNK/p38 signaling pathways and plays an essential role in regulating the cell response to the stresses and stress-induced apoptosis as well as to proliferation/survival signals. Merlin antagonizes CD44 function and inhibits activities of RTKs and the RTK-derived growth and survival signals. CD44 function upstream of mammalian Hippo signaling pathway attenuates the stress induced activation of the hippo signaling pathway, however, enhances activities of RTKs.

References

    1. Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, Harris R. A clinical study of type 2 neurofibromatosis. Q. J. Med. 1992;84(304):603–618. - PubMed
    1. Kluwe L, Bayer S, Baser ME, Hazim W, Haase W, Funsterer C, Mautner VF. Identification of NF2 germ-line mutations and comparison with neurofibromatosis 2 phenotypes. Hum. Genet. 1996;98(5):534–538. - PubMed
    1. Gutmann DH, Giordano MJ, Fishback AS, Guha A. Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas. Neurology. 1997;49(1):267–270. - PubMed
    1. Evans DG. Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]. Genet. Med. 2009;11(9):599–610. - PubMed
    1. Welling DB, Packer MD, Chang LS. Molecular studies of vestibular schwannomas: a review. Curr. Opin. Otolaryngol. Head Neck Surg. 2007;15(5):341–346. - PubMed

Publication types

Substances